Last updated: February 15, 2026
Overview of the Product
NDC 52427-0632 corresponds to the drug Ruxolitinib (brand name Jakafi), indicated for myelofibrosis, polycythemia vera, and graft-versus-host disease. Ruxolitinib is a Janus kinase (JAK) inhibitor developed by Incyte, approved by the FDA in 2011.
Market Landscape
Prevalence & Demand: Ruxolitinib addresses rare hematologic conditions. The global prevalence for myelofibrosis is approximately 3-6 per 100,000, with higher incidence in older adults. Polycythemia vera affects roughly 2-3 per 100,000 people. The demand remains stable for approved indications, with expansion potential into additional autoimmune and inflammatory conditions.
Market Size: Estimated U.S. prescriptions in 2022 totaled approximately 8,000-10,000 annually, with steady growth forecasted at a compound annual growth rate (CAGR) of 4-5% over the next five years driven by increased diagnosis rates and potential label expansions.
Competitive Environment: Jakafi faces competition from other JAK inhibitors such as Fedratinib (Inrebic) and potential future entrants like itacitinib. However, Jakafi maintains a near-monopoly in specific indications due to its established efficacy and safety profile.
Pricing Benchmarks: As of 2023, the wholesale acquisition cost (WAC) for Jakafi is approximately $8,980 per month per patient, translating into annual costs around $107,760 [1]. Patient access programs and insurance coverage significantly influence net prices.
Price Projections
Factors Influencing Future Pricing
-
Patent and Exclusivity Status: Jakafi’s patent expired in 2022 in several jurisdictions, with data exclusivity extending to 2027. Generic entry expected between 2023-2024, which will pressure list prices downward.
-
Generic Competition: Anticipated launch of generic ruxolitinib is projected for late 2023 or early 2024. Competitive pricing could reduce list prices by 60-70%, depending on market penetration.
-
Market Dynamics: Insurers and pharmacy benefit managers are likely to negotiate rebates, reducing the net price by 20-40% from WAC.
-
Regulatory and Reimbursement Policy: Price controls or value-based pricing initiatives may influence future list prices, especially as biosimilars or alternatives develop.
Projected Price Trajectory
| Period |
Price Range (WAC) |
Expected Changes |
| 2023 (Current) |
$8,980 monthly per patient |
No generic; stable pricing |
| 2024 |
$2,690 - $4,340 monthly |
Entry of generics; price decline begins |
| 2025-2026 |
$2,690 - $3,780 monthly |
Generics market share increases |
Note: Actual net prices will vary based on rebates, discounts, and negotiations.
Socioeconomic and Regulatory Factors
- Increasing emphasis on cost-effective care may lead to price caps or value-based agreements.
- Off-label uses and expanded indications under clinical investigation could influence demand and pricing.
Strategic Recommendations
- For biosimilar developers, market entry benefits from rapid commercialization post-patent expiry, targeting reducing list prices by at least 50%.
- Investors should monitor regulators’ stance on drug pricing and patent litigation post-expiration, which could accelerate or delay generic entry.
Key Takeaways
- Ruxolitinib’s original WAC price is approximately $8,980/month.
- Generic competition is expected to appear by late 2023 or early 2024.
- Premium pricing persists amid brand exclusivity; expect a significant drop with generics.
- Market demand remains stable for current indications, with potential expansion.
- Price negotiations and rebates significantly influence net prices; gross-to-net discounts can reach 40%.
FAQs
-
How soon will generic ruxolitinib enter the market?
Likely late 2023 to early 2024, following patent and exclusivity expiry.
-
What will be the impact of generics on Jakafi’s price?
List prices could decrease by 60-70%, substantially reducing revenue per unit.
-
Are there biosimilar options?
No, as Jakafi is a small-molecule drug, not a biologic, biosimilars are not relevant.
-
How does the market trend affect R&D investments?
Stable demand for current indications supports ongoing R&D; future expansion into new areas could sustain or increase investment.
-
What are the key regulatory challenges post-generic entry?
Potential patent litigations, reimbursement negotiations, and regulatory price controls could influence market dynamics.
Sources
[1] IQVIA data, 2023; Incyte financial reports; publicly available FDA approval and patent documents.
